
Clearside Biomedical, Inc. Common Stock (CLSD)
Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing therapies for the treatment of ocular diseases. The company specializes in entregaric drugs with its proprietary Suprachoroidal Space (SCS) delivery platform, which enables targeted delivery of medications to the back of the eye. Clearside's pipeline includes treatments aimed at retinal diseases, uveitis, and other vision-threatening conditions.
Company News
Multiple healthcare stocks experienced significant pre-market price movements, with some companies seeing notable gains while others faced declines.
The age-related macular degeneration (AMD) market is expected to grow due to the launch of new therapies and increased healthcare spending. Dry AMD and wet AMD are the two main types, with new treatments in development for both.
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of -21.43% and 76.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Retail traders are watching these penny stocks, here's why The post Retail Traders Are Watching These Penny Stocks in March 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.